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1. Introduction 
Endoscopic ultrasound (EUS) was introduced in clinical practice in 19801 and during the last 
few decades the quality of instrumentation has improved significantly. The first 
commercially available radial echoendoscope was introduced in Japan 2 and then in Europe 
3 in the mid to late 1980s. At that time, radial probes were used for fine needle aspiration 
(FNA). Only in the early 1990s EUS-FNA become technologically practical with the 
introduction of linear echoendoscopes that generated ultrasonic images parallel to the shaft 
of the instrument. With this modification, needles could be guided into areas of interest. 
Soon after this improvement, the first report of EUS-FNA of the pancreas was published 4 
and numerous other publications have followed 5-8. Later on, mechanical probes have been 
replaced by electrical probes that allowed expansion of the diagnostic capacity of EUS. More 
recently, the addition of color Doppler ultrasonography, injection of contrasts for ultrasound 
and the application of elastography has further extended the clinical use of EUS for 
hepatobiliary and pancreatic diseases. The fact that EUS is able to provide direct 
visualization of the walls of the gastrointestinal tract and direct the placement of needles for 
cytology or histology specimens 5,9, makes this technique very useful for the diagnosis of 
benign and malignant diseases of these organs that are difficult to reach percutaneouly. In 
recent years diagnostic modalities such as multidetector-multiphasic CT with pancreatic 
protocols, magenetic resonance imaging (MRI) and positron emission tomography (PET) 
scans have improved significantly the pre-operative tumor staging of pancreatic 
malignancies. Nevertheless, a significant proportion of patients will benefit from EUS-FNA 
for confirmation of pancreatic neoplasm and assessment of the planes along the vascular 
superior mesenteric trunk10.  
2. Epidemiology of pancreatic neoplasms 
Pancreatic adenocarcinoma is the fourth leading cause of cancer related mortality in the 
United States with estimated 42,500 new cases and 35,000 deaths from the disease each year 
11. In industrialized countries, the incidence of pancreatic adenocarcinoma (11 per 100,000 
individuals) ranks second after colorectal cancer among all gastrointestinal malignancies12. 
More than 80% of PCs are diagnosed in patients older than 60 and almost 50% have distant 
metastases at the time of presentation13,14. Men are more frequently affected than women 
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(Relative Risk (RR) = 1.3) and individuals of African American descent in comparison to 
Caucasians (RR= 1.5) 15. Analysis of overall survival shows that the prognosis of PC is still 
quite poor despite the fact that 1-year survival has increased from 15.2% (period between 
1977-1981) to 21.6% (period between 1997-2001) and 5-year survival has increased from 3% 
(period between 1977-1986) to 5% (period between 1996-2004)16.  
3. Classification of pancreatic neoplasms 
The vast majority (90%) of pancreatic cancers (PC) are malignant tumors originating from 
pancreatic ductal cells 17. Anatomically, 78% of PCs are located in the head, and the 
remaining 22% are equally distributed in the body and in the tail18. The most common  
 
EPITHELIAL TUMORS NON-EPITHELIAL TUMORS 
Benign Pancreatic Tumors Endocrine Tumors
  Serous Cystoadenoma  Insulinoma (Incidence: 70-80%) 
  Mucinous Cystoadenoma  Gastrinoma (Incidence: 20-25%) 
  Intraductal Papillary Mucinous 
Neoplasm (IPMN)
  VIPoma (Incidence: 4%) 
Mature Teratoma  Glucagonoma (Incidence: 4%)
Borderline Pancreatic Tumors  Somastatinoma (Incidence: <5%) 
  Mucinous Cystic Neoplasm with 
Moderate Dysplasia
  Carcinoid (Incidence: <1%) 
  Intraductal Papillary Mucinous 
Neoplasm with Moderate Dysplasia
  ACTHoma (Incidence: <1%) 
  Solid-pseudopapillary Neoplasm 
(SPPN) 
  GRFoma (Incidence: <1%) 
Malignant   PTH-like-oma (Incidence: <1%) 
  Ductal Adenocarcinoma  Neurotensinoma (Incidence: <1%) 
  Mucinous non-cystic carcinoma  Non-functional tumors (Incidence 30-50%) 
  Signet ring cell carcinoma Mesenchymal Neoplasms
  Undifferentiated (anaplastic) carcinoma  Leiomyoma
  Undifferentiated carcinoma with 
osteoclast-like giant cells
  Lipoma 
  Mixed ductal-endocrine carcinoma  Neurofibroma - Ganglioneuromas  
  Serous Cystoadenocarcinoma  Hemangyoma - Lymphangioma 
  Mucinous Cystoadenocarcinoma  Granular Cell Tumors
  Intraductal Papillary-Mucinous 
Carcinoma 
  Schwann Cell Tumors 
  Acinar Cell Carcinoma  Gastrointestinal Stroma Tumors (GIST) 
  Medullary Carcinoma  B-cell Lymphomas
  Acinar Cell Cystoadenocarcinoma Metastatic Tumors
  Pancreatoblastoma Renal Cell Carcinoma 
Melanoma  
Breast Cancer  
Squamous Cell Carcinoma  
Endometrioid Adenocarcinoma  
Osteosarcoma
  Solid-pseudopapillary Carcinoma
Others 
  Secondary Tumors 
Table 1. Tumor Classification  
www.intechopen.com
 
Endoscopic Ultrasound for Solid and Cystic Neoplasms of the Pancreas 
 
309 
clinical presentations are progressive weight loss and anorexia, mid abdominal pain and  
jaundice. Pancreatic neoplasms are classified in benign or malignant according to the 
cytological characteristics. These can be further divided into endocrine or exocrine tumors 
according to the function of their cells and into cystic or solid according to the macroscopic 
features of the lesion. Recent advances in surgical pathology techniques integrated with 
molecular biology have allowed advances in the modern classification of pancreatic 
neoplasms. A summary of the clinico-pathological features of the different categories of 
pancreatic lesions is shown in Table 1. 
4. Conventional diagnostic modalities for pancreatic cancer 
4.1 Abdominal ultrasound  
Trans-abdominal ultrasound (US) is often used as a screening test 19. Its sensitivity ranges 
between 48% 8 and 89% 20 with accuracy between 46% 8 and 64%21. Small tumors measuring 
less than 1cm are detected by US in only 50% of cases while the sensitivity increases to 
95.8% for tumors larger than 3 cm20. US has a relatively low performance profile for staging 
of pancreatic tumors as  its sensitivity for lymph nodes involvement ranges only between 8 
17 to 57 % 20. Color Doppler US has been used to assess possible involvement of the portal 
vein and superior mesenteric vessels with a sensitivity ranging between 50% 22 and 94% 23 
specificity between 80% and 100% 22 and accuracy between 81% and 95% 19. 
4.2 Computed Tomography  
On contrast CT, pancreatic adenocarcinoma appears as an ill-defined, hypo attenuating focal 
mass with dilatation of the upstream pancreatic and or biliary duct 24. The optimum 
visualization of the pancreas requires imaging acquisition obtained during both arterial and 
portal phases 25 with sensitivity and specificity of 77% and 100% respectively for lesions less 
than 2 cm 26. In a multicentric trial, the diagnostic accuracy of contrast CT for resectability was 
73% with 90% PPV for non resectability 27. With the advent of multi detector CT scanners 
(MDCT) the pancreas can be imaged at a very high spacial and temporal resolution28,29. Recent 
studies have shown that NPV for respectability was 87% for MDCT compared to 79% for 
conventional helical CT 30 and with accuracy between 85% and 95% 31,32.  
4.3 Magnetic Resonance Imaging (MRI-MRCP)  
In most institutions, MRI is performed when other imaging modalities provide insufficient 
data for the clinical staging of the tumor or when treatment planning can not be based on 
the images obtained by other techniques. Several studies have shown that MRI is superior to 
CT scan for the detection and staging of pancreatic adenocarcinoma (100% vs. 94% 
respectively)33-36. The use of MRI-MRCP for pancreatic malignancies is supported by a 
prospective analysis showing that MRI-MRCP was superior to CT in differentiating 
malignant from benign lesions and MRI-MRCP had better sensitivity (92% vs. 76%), 
specificity (85% vs. 69%), accuracy (90% vs. 75%), PPV (95% vs. 88%) and NPV (79% vs. 
50%) compared to CT 37.  
4.4 Positron Emission Tomography  
18F-2fluoro-2-deoxy-D-glucose (FDG) accumulated by tumor cells provides PET the 
advantage of combining metabolic activity and imaging characteristics. Newly developed 
PET scanners can detect small PC up to 7mm in diameter and diagnose metastatic disease in 
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about 40% of cases38,39. A Japanese study found that the overall sensitivity of PET-CT was 
superior to contrast CT (92% vs. 88%) and that PET was better at detecting bone metastases 
(100% vs. 12%). However, CT scan was superior for the evaluation of vascular invasion 
(100% vs. 22%), involvement of para-aortic regional lymph nodes (78% vs. 57%), 
identification of peritoneal dissemination (57% vs. 42%) and hepatic metastases (73% vs. 
52%) 40.  
4.5 Treatment of pancreatic neoplasms 
Solid tumors of the pancreas are typically associated with malignancy, whereas cystic 
tumors more often tend to be benign41. Due to the difficulties in differentiating benign from 
malignant lesions, resection is often indicated when patient’s conditions and tumor stage 
allows it 42. Surgical resection with negative margins is the only potential curative treatment 
for pancreatic malignancies but unfortunately, even when surgery is performed 
successfully, recurrent disease is frequent and long term survival is expected only for 5-15% 
of patients17. According to the United States Surveillance and Epidemiology End Results 
registries, the 5-year relative survival for the period between 1999 and 2006 was 22.5% for 
localized and 1.9% for metastatic tumors 43. The majority of tumors are diagnosed when 
locally advanced or with early metastases, and only 20% are suitable for resection at the 
time of diagnosis. Despite the improvements in surgical techniques and advances in 
perioperative supportive care that have reduced the mortality rates to less than 5% in high 
volume centers, pancreatic surgery remains challenging 44-46.  Therefore, pre-operative 
accurate staging is fundamental in identifying patients who would benefit from surgery. 
EUS has been shown to play an important role in preoperative diagnosis and tumor staging 
as it provides high resolution images of the pancreas without interference of bowel gas 47. 
4.6 EUS equipment and techniques 
EUS is usually performed with patients positioned in the left dcubitus and under conscious 
sedation. The transducer located in the tip of the oblique-viewing fiberscope is inserted as 
far as the second portion of the duodenum, and scanning is done with a de-areated water 
filled ballon applied to the tip of the echoendoscope. After examination of the pancreatic 
head, the ecoendoscope is drawn backward to the stomach, and EUS of the body and tail of 
the pancreas is performed. The frequency usually used to assess the pancreas and 
surrounding organs during EUS ranges between 5 and 12 MHz 48. During the last decade, 
intraductal US (IDUS) has been possible by the introduction of miniprobes measuring 1.7-
2.4 mm in outer diameter that can be advanced in the common bile and pancreatic ducts 
utilizing scanning frequencies ranging between 10-30MHz and obtaining a maximum tissue 
view penetration of approximately 2 cm 1,48. The miniprobe is initially introduced into the 
papilla of Vater and advanced into the pancreatic or bile duct beyond the area of interest 
and then it is slowly pulled back. The location of the miniprobe can be confirmed by using 
fluoroscopy as it is usually done during regular endoscopic retrograde cholangio-
pancreatography (ERCP). IDUS is able to visualize only limited parts of the pancreas and 
surrounding structure such as the splenic vessels, portal vein, superior mesenteric artery 
and vein and extrahepatic duct.  
4.7 Indications for Endoscopic Ultrasound and Fine Needle Aspiration (EUS-FNA) 
The most common indication for EUS-FNA of the pancreas is for evaluation of pancreatic 
masses with atypical characterisitics on cross sectional images or for optimal pre-operative 
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staging (Table 2). Differential diagnosis of pancreatic masses includes malignant and benign 
neoplasms, chronic pancreatitis, lymphoma and metastases. Approximately 90% of 
pancreatic neoplasms are adenocarcinomas, 5% are cystic lesions, and 2-5% are 
neuroendocrine tumors. Metastatic lesions to the pancreas, primarily from renal cancer, 
lung cancer, and lymphomas represent a small percentage. Because cystadenocarcinomas49 
and neuroendocrine tumors50 have a significantly better prognoses than pancreatic 
adenocarcinoma, accurate cytologic preoperative identification can significantly alter the 
subsequent management of these patients51. In general, EUS has been shown to be superior 
to CT, MRI, and ERCP 52 in the diagnosis of pancreatic diseases as an imaging modality  
2,5,53,54. The current sensitivity of EUS is in the range of 95-100%. During the last decades, the 
diagnostic advantages of EUS for pancreatic pathology have been challenged by the 
advances of other cross sectional modalities such as CT, MRI and PET scans 55 56. When 
combined with FNA capabilities, EUS has the advantage of being able to sample suspicious 
lesions. The one area where malignancies can be still easily missed by EUS, even with EUS-
FNA, is in the setting of underlying chronic pancreatitis4,53,57-59. No single or combination of 
imaging modalities has yet proven accurate in definitively determining when a patient with 
chronic pancreatitis has developed pancreatic cancer. The technique of EUS-guided FNA 
involves passing an 18 to 22 gauge metal needle through the biopsy port of a linear 
echoendoscope under real-time guidance into an endosonographically visualized pancreatic 
mass. The needle is then moved back and forth several times (5-10 passes) with varying 
degrees of negative pressure to collect cells or small tissue samples that are then deposited 
on cytology slides for immediate fixation and staining 60. EUS-FNA of primary pancreatic 
malignancies is able to provide a definitive diagnosis in 80-93% of cases 8,54,57,61-63. The ability 
to have a cytopathologist on site who can provide immediate feedback on the quality and 
adequacy of the specimens obtained by FNA is extremely important for the accurate 
diagnosis62,63. Choosing what part of a pancreatic mass to aspirate is something of an art and 
comes with experience. The most difficult pancreatic masses to aspirate are the ones located 
near the uncinate process as it can be very hard to direct the needle to enter the lesion 
around the second and third portion of the duodenum. The best yield of diagnostic cells 
usually seems to come from 1 cm to 2 cm deep to the margin of the tumor. Color flow 
Doppler can be used prior to EUS-FNA to help avoid vessels overlying the proposed path of 
the aspiration needle such as are seen when there is underlying portal vein or splenic vein 
obstruction. Similarly to CT and ultrasound-guided FNA or biopsy, the overall complication 
rate secondary to EUS-FNA of the pancreas is about 1-2% 6,8,58,61,64. The major complications 
reported with EUS-FNA are bleeding, pancreatitis, and infection but mortality is very rare  
 
Indications for EUS 
Acute onset of diabetes in elderly patients 
Involuntary weight loss 
Presence of epigastric or back pain 
Acute or chronic pancreatitis 
Suspected pancreatic cancer on other cross sectional imaging modalities 
Family history of pancreatic cancer or presence of genetic predisposition to pancreatic 
cancer 
Table 2. Common Indications for Endoscopic Ultrasound  
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and usually caused by uncontrollable hemorrhage65 that is more likely when the patient has 
portal hypertension. Pancreatitis after EUS-FNA is most likely to occur in patients already 
being evaluated for recurrent pancreatitis and when the FNA needle is passed through more 
than 2 cm to 3 cm of normal pancreas to obtain a specimen. Bacteremia following EUS-FNA 
for solid tumors is quite uncommon while EUS-FNA of cystic pancreatic lesions has a higher 
risk of infectious complications and broad-spectrum intravenous antibiotics are routinely 
recommended. The risk of cancer seeding by EUS-FNA appears to be significantly lower 
when compared to percutaneous FNA 66. 
4.8 EUS-FNA for benign pancreatic lesions 
Indications and impact of EUS-FNA for benign disease other than pancreatic cystic lesions is 
still in evolution as it appears to be safe but does not add significantly to the diagnostic 
accuracy of EUS or other cross sectional imaging tests67. 
4.9 Ultrasonographic characteristics 
Pancreatic adenocarcinoma often appears as a mass with irregular echogenicity due to the 
irregulary arranged carcinomatous canaliculi or coagulative necrosis of the neoplastic cells 
superimposed on a hypoechoic background 68. Small pancreatic cancers instead, can often 
have homogeneous and hypoechoic echogeneicity that can mimic benign diseases such as 
focal pancreatitis, pseudotumors or islet cell neoplasms that have clear margins, smooth 
contour and regular central echogenicity48. When compared to CT scan and ERCP, EUS 
performs better for the detection of small pancreatic cancers (less than 2 cm in diameter) and 
it is currently indicated when patients are suspected to have early stage tumors or when 
undergoing screening for familial pancreatic cancer as it is the most sensitive diagnostic test 
for lesions measuring less than 1 cm in diameter 69,70. 
5. Differential diagnosis of pancreatic lesions 
Differentiation between pancreatic malignancies from inflammatory masses has been very 
challenging with the use of cross sectional imaging modalities such as US, CT scans, MRI 
and ERCP. EUS-FNA appears to be the best diagnostic strategy as it combines the ability of 
ultrasound imaging of the pancreatic lesions and the ability of obtaining samples for 
cytological or histological evaluation. Recent studies have reported that adequate specimen 
acquisition is possible in 97% of cases with accurate differential diagnosis in 87% of patients 
48. Sensitivity, specificity, positive predictive value and negative predictive value for EUS-
FNA were: 85%,100%, 100% and 53% respectively48 (Table 3). One of the major pitfalls is 
over interpretation of a lesion as positive for malignancy as a result of contamination of 
dysplastic cells when the needle traverses an area of high-grade dysplasia of the 
gastrointestinal tract mucosa. It is equally important that benign mucosal glandular cells in 
the aspirate of the lymph node not be over interpreted as metastasis. Although EUS-FNA is 
a very useful diagnostic technique for the differential diagnosis of patients with pancreatic 
lesions, it has to be kept in mind that even if the results of the test are negative for 
malignancy, pancreatic cancer can not be completely excluded. Currently, EUS-FNA should 
be still used in conjuction with other imaging modalities and repeated when clinical 
suspicion is suggestive for the possibility of malignancy (Table 4).  
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Diagnostic Performance CT EUS EUS-FNA 
Sensitivity 63-84% 95-100% 79-95% 
Specificity 35-93% 19-81% 69-100% 
Negative Predictive Value 12-49% 48-100% 31-78% 
Positive Predictive Value 89-99% 85-98% 94-100% 
Accuracy 70-88% 97-98% 81-96% 
Table 3. Diagnsostic Performance of Endoscopic Ultrasound and Computerized 
Tomography for Solid Pancreatic Cancers 
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Sensitivity 63-84% 95-100% 79-95% 
Negative Predictive Value 12-49% 48-100% 31-78% 
Positive Predictive Value 89-99% 85-98% 94-100% 
Accuracy 70-88% 97-98% 81-96% 
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Sensitivity 51-80% 92-100% 71-94% 
Specificity 16-100% 1-99% 16-100% 
Negative Predictive Value 1-36% 25-100% 3-60% 
Positive Predictive Value 88-100% 88-100% 91-100% 
Accuracy 53-81% 89-100% 72-94% 
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Sensitivity 70-98% 87-100% 80-100% 
Specificity 24-91% 16-84% 63-100% 
Negative Predictive Value 24-91% 40-100% 52-100% 
Positive Predictive Value 70-98% 69-96% 86-100% 
Accuracy 65-93% 73-97% 85-100% 
Table 4. Diagnostic Performance of Endoscopic Ultrasound with and without Fine Needle 
Aspiration in Comparison to Computerized Tomography for Pancreatic Cancers in the 
Presence and Absence of Obstructive Jaundice 
5.1 Cancer staging 
The accuracy of EUS for the stage of patients with pancreatic cancer is superior to  US and 
CT scans with values ranging between 85 and 100% in comparison to 64-66% for CT  and 61-
64% for US 55,71. The EUS accuracy in staging pancreatic cancer does not depend on the use 
of radial or linear scanners 65. Radial scanners offer a better overview of surrounding 
structures, whereas linear scanners allow the safe execution of tissue sampling. Initial 
studies showed excellent accuracy up to 94%, but later publication reported lower values 
ranging between 63% and 78% 55,72-76. Overall, EUS-FNA is highly sensitive (84%), specific 
(97%), accurate (84%) and has a high positive predictive value (99%), but relatively low 
negative predictive value (64%)77 (Table 5). A major problem in staging pancreatic cancer is 
the prediction of resectability as the best chance for long-term survival occurs in patients 
with localized disease undergoing resection. The primary goal of surgical therapy is to 
achieve a margin-negative R0 resection with minimal postoperative complications and a 
secondary important goal is to avoid unnecessary laparotomies for unresectable tumors78. 
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Combining the pre-operative utilization of CT and EUS proved to be the method with the 
highest accuracy compared to each single technique to predict tumor resectability79.  
In this context, a preoperative assessment of R0 resectability becomes critically important. 
Radiologic staging with EUS and CT or MRI is currently used to identify patients who may be 
resectable. The criteria of unresectability of pancreatic cancer include evidence of distant 
metastasis, tumor enchroachment (defined as tumor surrounding the vessel more than 180 
degrees) of arteries such as the celiac artery, hepatic artery, superior mesenteric artery (SMA) 
or massive venous invasion with thrombosis. Portal or superior mesenteric venous invasion 
without thrombosis or obliteration of vessels can still be classified as resectable tumors. A 
recent study comparing the roles of EUS, CT, MRI and angiography in the assessment of 
pancreatic cancer staging and respectability, has shown that CT scan was the most accurate in 
assessing the stage of the tumor (73%), locoregional invasion (74%), vascular involvement 
(83%), distant metastases (88%), final TNM stage (46%) and overall tumor resectablity (83%) 76. 
Although EUS appeared to be superior to detect smaller tumors not visualized by CT scan it is 
important to recognize that most surgeons would probably not rely on EUS alone before 
making important therapeutic decisions about surgical resections80.  
 
 No Discrete Mass  on CT Discrete Mass on CT Scan 
 EUS EUS-FNA EUS EUS-FNA 
Sensitivity 82-100% 65-99% 93-100% 77-96% 
Specificity 29-96% 59-100% 0-71% 29-100% 
Negative Predictive Value 48-100% 40-97% na 7-70% 
Positive Predictive Value 68-99% 79-100% 85-99% 92-100% 
Accuracy 63-99% 74-99% 85-99% 78-96% 
Table 5. Diagnostic Value of Performing EUS-FNA Along with Spiral CT in Patients with 
Suspected Pancreatic Cancer 
5.2 Conclusions 
EUS-FNA has greatly impacted the diagnostic management of patients affected by 
pancreatic masses in conjunction with other cross sectional imaging tests.  EUS is the best 
  
Suspected Pancreatic Cancer
Tumor not Detected by 
Cross-Sectional Imaging 
Studies
Resectable Tumor
Non-Resectable Tumor
EUS-FNA
Normal
Follow-up
Surgery
Palliation
Neoadjuvant Therapy
 
Fig. 1. Flow Chart for the Evaluation and Management of Patients with Suspected Pancreatic 
Malignancies 
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method for tissue diagnosis and it is extremely useful for the management of patients who 
are not surgical candidates and who require neo-adjuvant or palliative chemoradiation 
therapy. Conversely, pre-operative tissue diagnosis is not indispensable for resectable 
tumors and therefore EUS plays a lesser role in this group of patients. In recent years, EUS 
has assumed an important interventional role in the management of patients who are 
affected by debilitating pancreatic cancer pain as it is extremely useful in obtaining celiac 
plexus block for long term analgesic effects.  Current role of EUS and EUS-FNA is 
summarized in Figure 1. 
6. Pancreatic cystic lesions 
Pancreatic cystic lesions (PCLs) are commonly identified due to increased use of cross-
sectional imaging in patients with non-specific abdominal complaints. Although their exact 
prevalence is unknown, it is estimated to range from 1% to 2.6% of the general population 
based on large scale observational imaging studies using MDCT81,82. Pancreatic cystic 
lesions are strongly associated with increasing age and Asian race82. Their relative frequency 
varies substantially geographically and by institution (primary vs. secondary) due to 
different practices and patient populations 83. In addition, the prevalence of PCLs including 
intraductal papillary mucinous neoplasms (IPMNs) was found to be higher among patients 
on hemodialysis compared to the normal population 84. 
Inflammatory pseudocysts represent about 75% of pancreatic cysts; however they are not 
classified as true PCLs since they are non-epithelial inflammatory fluid collections 
associated with acute or chronic pancreatitis 85. Based on surgical pathology, PCLs are 
classified according to the characteristics of the cells lining the cyst in benign, premalignant 
and malignant 86(Table 6). 
Serous cystadenomas (SCAs), mucinous cystadenocarcinomas (MCAs) and IPMNs 
represent 90% of PCLs and only the mucin producing neoplasms have been described to 
have risk of malignancy 87. In a small percentage of patients, solid malignant tumors such as 
adenocarcinoma, neuroendocrine tumors and other less common causes can present with 
cystic degeneration 88.  
6.1 Limitations of radiological imaging modalities for the diagnosis of PCLs 
Trans-abdominal ultrasound (US) is a safe and cheap diagnostic modality that can be used 
to diagnose PCLs, however, its sensitivity and specificity are often affected by the operator’s 
experience and the technical characteristics of the machine 89. In addition, the deep position 
of the pancreas and the interposition of other organs such as the stomach and the transverse 
colon limit the capacity of US to identify small PCLs. The overall sensitivity of US in 
detecting pancreatic lesions ranges from 48% 8 to 89% 20.  
The majority of studies describing the role of CT and MRI in the diagnosis of PCLs have 
been small and retrospective. Relying on radiological characteristics alone can be 
misleading, with up to 40% of serous and mucinous lesions being misdiagnosed as 
pseudocysts 85,90. Reported overall diagnostic accuracy for these lesions has been highly 
variable ranging between 20% and 83% 91-93. (Table 7) 
In a large group of patients, accurate preoperative diagnosis of PCLs was reported in 20% 
for serous cystadenoma, 30% for mucinous cystadenoma and 29% for mucinous 
cystadenocarcinoma, as the majority of these lesions were misdiagnosed as pseudocysts 92. 
MRI is equal or slightly superior to CT in diagnosing PCLs except in its limited ability to 
demonstrate calcifications in the tumor wall or septa 94.  
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Pseudocysts (no epithelial lining) 
Conventional pseudocysts 
Paraduodenal wall cyst (cystic dystrophy) 
Infection-related pseudocysts 
 
Cysts with mucinous epithelium 
Intraductal papillary mucinous neoplasms  
Intraductal oncocytic papillary neoplasms 
Mucinous cystic adenoma 
Mucinous cystic adenocarcinoma 
Mucocele 
Retention cysts 
 
Serous (clear-cell) cystic tumors 
Serous cystadenoma 
VHL-associated pancreatic cysts 
Serous cystadenocarcinomas (Extremely rare, case reports) 
 
Squamous-lined cysts 
Lymphoepithelial cysts 
Epidermoid cysts within intrapancreatic accessory spleen 
Dermoid cysts 
Squamoid cyst of pancreatic ducts 
 
Cysts lined by acinar cells 
Acinar cell cystadenocarcinomas 
Acinar cell cystadenomas (cystic acinar transformation) 
 
Endothelial-lined cysts 
Lymphangiomas 
 
Degenerative or necrotic changes in solid tumors 
Solid-pseudopapillary tumor 
Cystic change in ordinary ductal adenocarcinoma 
Cystic pancreatic endocrine neoplasia (islet cell tumors) 
Cystic mesenchymal neoplasms 
 
Other rare cystic lesions 
Cystic hamartomas 
Endometriotic cyst 
Metastatic cystic neoplasms 
Congenital or developmental cysts 
Others 
VHL= Von Hippel-Lindau 
Table 6. Pancreatic cystic lesions classified by cells lining the cavity 
www.intechopen.com
 
Endoscopic Ultrasound for Solid and Cystic Neoplasms of the Pancreas 
 
317 
For IPMN, magnetic resonance cholangiopancreatography (MRCP) seems to be superior to 
endoscopic retrograde cholangiopancreatography (ERCP) in detecting cysts communicating 
with the main pancreatic duct 95. 
6.2 Endoscopic ultrasonography 
Endoscopic ultrasound (EUS) allows high resolution imaging of the pancreas with the 
ability to provide fine morphological details. The combination of fine-needle aspiration 
(FNA) cytology with the other recently available diagnostic markers has further increased 
its diagnostic accuracy96. Indications for EUS-FNA should be considered based on 
diagnostic accuracy of alternative modalities, costs, patient comfort and safety 97 and should 
be performed only when the information obtained has the potential to alter patient’s 
management 98. EUS-FNA should not be performed when there is inability to clearly 
visualize the target lesion, presence of large vessels interposed in the path between the 
needle and the lesion, bleeding diathesis and for patients at high risk of tumor seeding 98 
such as those with cholangiocarcinoma who are considered for liver transplantation 99. Once 
a cystic lesion is identified, the main clinical issue is the characterization and eventual 
therapeutic approach. Diagnostic accuracy of EUS imaging alone for differentiating 
malignant versus premalignant or benign lesions is ranging between 82% and 96% 100-103. 
The endosonographic features suggestive of malignancy are: wall thickness of 3 mm or 
greater, macroseptations with cystic compartments greater than 10 mm, presence of a mass 
or intramural growth or cystic dilation of the main pancreatic duct. These features have a 
sensitivity of 91%, a specificity of 60% and an accuracy of 72% in predicting malignant or 
potentially malignant PCLs 104. The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy of EUS in comparison to other imaging 
modalities is summarized in Table 7 
Despite EUS alone is a very sensitive test, EUS-guided fine needle aspiration (FNA) 
provides additional information for the characterization of PCLs. In a study by Frossard et 
al., the results of EUS and EUS guided FNA were compared with the final surgical 
pathology report. The sensitivity, specificity, PPV and NPV of EUS-guided FNA in this 
study were 97%, 100%, 100% and 95% respectively102.  On the other hand, corresponding 
values for EUS imaging alone were 71%, 30%, 49% and 40% respectively102. Yet, the overall 
sensitivity and accuracy of EUS-FNA cytology remains widely variable with average 
sensitivity and accuracy around 50% 62,103,112,113. 
6.3 Cytology 
The aspirated cyst fluid is generally analyzed for tumor markers, chemical and molecular 
analysis. Solid component associated with PCLs or regional lymph nodes can be aspirated 
for cytology or histology. EUS guided FNA is safe and rare complications include 
pancreatitis (2-3%), intracystic hemorrhage (<1%) and infection (<1%). The administration of 
antibiotic during the procedure is a common practice even if there are no data to support it 
114. Tumor cell seeding has been a significant concern; there is limited evidence on the actual 
rise of tumor spread by EUS-FNA 115. Recent study has shown that EUS-FNA has a 
decreased risk of peritoneal tumor spread as compared with computed tomography-guided 
FNA (2.2% vs. 16.3%) 66. During EUS-FNA, the operator should always avoid to insert the 
needle through malignant tissue to reach a suspicious lesion. An example of this may be a 
patient with gastric or esophageal cancer and a suspicious lymph node adjacent to the 
primary tumor as the needle would have tumor entrapped into the channel that could 
contaminate the final results. 
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Diagnostic 
modality 
Author Year 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Accuracy 
(%) 
US 
Giovanni et al8 1994 
48-95 40-91 92 100 46-64 
Bottger et al20 1998 
Rosch et al3 1991 
Niederau et al105 1992 
Palazzo et al21 1993 
Tanaka et al106 1996 
Doppler US 
Candiani et al107 1998 
50-94 80-100 79 88 81-95 Casadei et al23 1998 
calculli et al108 2002 
EUS 
Akahoshi et al72 1998 
98 97 94 100 90 Sedlack et al104 
Legmann et al55
2002 
1998 
Contrast 
enhanced US 
Dietrich et al109 2008 90 100 100 86 93 
CT 
Bronstein et al26 2004 
77 100 na na 73 
Megibow et al27 1995 
MDCT 
Park et al110 2009 
83-91 63-75 80 87 85-95 
Vargas et al30 2004 
Diehl et al31 1998 
Schima et al33 2002 
MRI-MRCP Anderssonet al37 2005 83-92 63-85 95 79 89 
PET 
Maemura et al38 2006 
87-100 67-77 94 100 85-95 
Delbeke et al111 1999 
Abbreviations: Ultrasound (US), Endoscopic ultrasound (EUS), Computed tomography (CT), Multi 
detector computed tomography (MDCT), Positron emission tomography (PET) 
Table 7. Summary of the performance characteristics of imaging tests for the diagnosis of 
pancreatic cancer 
6.4 Cystic fluid markers  
Several markers can be measured in the fluid aspirated from the pancreatic lesions during 
EUS to differentiate mucinous from non mucinous cysts. The most commonly used are; 
CEA, carbohydrate antigen (CA) 19-9, CA 72-4, and CA 15-3 116. CEA appears be the most 
useful as levels higher than 192 ng/ml had an accuracy of 79% for mucinous lesion 
characterization and was superior to cytology and EUS morphology 103.  
Other markers such as amylase and lipase are important in the evaluation of cystic 
pancreatic lesions. Amylase is usually elevated in inflammatory cysts like pseudocysts but 
also in IPMN due to communication between the cystic lesion and the pancreatic duct. 
Amylase level less than 250 U/L favors the diagnosis of benign or malignant cystic 
neoplasms versus pancreatic pseudocysts (sensitivity 44%, specificity 98%) 117.  
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Molecular markers are recently considered a more reliable alternative. A multicenter study 
on pancreatic cyst fluid DNA analysis demonstrated a strong association of mucinous cystic 
neoplasms with K-ras mutations occurring with other loss of heterozygosity (LOH) 
mutations118. Shen et al 119 assessed the correlation between this molecular diagnosis with a 
clinical consensus diagnosis for PCLs defined by histology, malignant cytology, or two 
concordant tests (such as EUS, cytology, or CEA>_192 ng/ml for mucinous cysts). The study 
showed that the two diagnostic methods correlated well and molecular analysis of 
pancreatic cyst fluid added diagnostic value to the preoperative diagnosis. 
7. Conclusion 
Pancreatic cystic lesions are detected more frequently than in the past due to more sensitive 
imaging modalities. The differentiation between benign and malignant cystic lesions is often 
challenging. EUS and EUS-FNA have become a leading modality for the differential 
diagnosis of these lesions as it provides imaging characteristics and the possibility of 
obtaining cytology or fluid samples with high sensitivity and specificity. Characterization of 
cystic morphology by other imaging studies should be supplemented by EUS-FNA as 
cytology, tumor markers and DNA analysis can further characterize these lesions and 
increase the diagnostic accuracy of premalignant and malignant cysts. 
8. Summary 
Despite the advancement of other cross sectional imaging tests, EUS appears to have a 
higher sensitivity in detecting small pancreatic neoplasms in comparison to CT. On the other 
hand EUS does not appear to be accurate enough in assessing the invasion of SMA and SMV 
and respectability of locally advanced tumors. Recent studies have shown improved 
diagnostic performance of EUS with the use of parenteral contrast agents and EUS-FNA 
plays a key role when. tissue diagnosis is needed.  
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